Notably, EphA3 is implicated and recognised as an anti-cancer target in solid and hematopoietic tumors [33], and we recently discovered EphA3 overexpression and function on bone marrow-derived MSCs that are recruited into the vascularised tumour microenvironment [34]. The gene discussed is EPHA3; the disease is neoplasm.